$DNLI: The Week Ahead In Biotech: Conferences, Clinical Trials And …

Date: Saturday, December 8th, 2018

Stock(s) mentioned:

Source: Benzinga (https://www.benzinga.com)

Summary: Denali Therapeutics Inc (NASDAQ: DNLI) is scheduled to present Phase 1 data for its Alzheimer’s disease candidate DNL747 at its R&D Day Monday, Dec. 10.

Full article address: https://www.benzinga.com/general/biotech/18/12/12807823/the-week-ahead-in-biotech-conferences-clinical-trials-and-earnings

Related News:

$DNLI $EVLO: Flagship Pioneering Expands Growth Capabilities, Announces …

$DNLI $GH $VRA $YETI: Outside the Box: Harry Boxer’s 4 stocks running on earnings

$DNLI: AbCellera and Denali Therapeutics Sign Expanded Multi-Year, Multi …

$DNLI: Early-stage study of Denali’s Alzheimer’s candidate DNL747 …

$DNLI: Exclusive: Quietly, Gladstone founder’s new company plots unique …

$DNLI: Denali teams up with Sirion in gene therapies

$DNLI: SIRION Biotech and Denali Therapeutics Join Forces to Develop …

$DNLI $EVLO: Cygnal Therapeutics Appoints Pearl S. Huang as Chief Executive …

$CWT $CENT $DNLI: Do Hedge Funds Love Atlantica Yield plc (AY)?

$DNLI $EVLO: Therapeutics appoints Carl P. Decicco, Ph.D. as Chief Scientific Officer

$DNLI $SNY: Health Care Digest: Genentech’s blood cancer win, a boost for …

Latest News:

$TSLA: Registration data suggests slump in Tesla sales

$T $VIA: AT&T Pushes Xandr Ad Products in Viacom Carriage Talks

$VIX: From Lyft to Airbnb, new round of IPOs is no market top: Nick Colas

$ASND: Ascendis Pharma Announces Phase 3 heiGHt Trial Demonstrated …

$MKC: McCormick Earnings: What to Watch

$DWDP: Is DowDuPont a Buy?

$T $VIA: Viacom and AT&T Negotiate to Avert Major Programming Blackout

$MGM $CZR $VICI: How Wynn Resorts Could Free Up Billions in Cash

$PYX $RKDA: CBD is booming. But US farmers struggle to keep up with demand for industrial hemp

$GE: 3 Stocks Looking to Benefit From GE’s Misfortunes

$LEVI: Before the Levi’s IPO, there was the 1985 buyout led by iconoclastic S.F. investor Warren Hellman